COST-EFFECTIVENESS ANALYSIS OF PROLANIS OF TYPE 2 DIABETES MELLITUS PATIENTS ON THREE COMMUNITY HEALTH CENTERS IN BANDUNG, INDONESIA

RIANI TANJUNG; YULIA WARDATI; NYI MEKAR SAPTARINI

doi:10.22159/ijap.2021.v13s3.05

Authors

RIANI TANJUNG Departement of Accounting, Pos Indonesia Polytechnic, West Java, Indonesia 40151
YULIA WARDATI Departement of Pharmacy, Faculty of Mathematic and Natural Sciences, Al Ghifari University, West Java, Indonesia 40293
NYI MEKAR SAPTARINI Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, West Java, Indonesia 45363

DOI:

https://doi.org/10.22159/ijap.2021.v13s3.05

Keywords:

Puskesmas, Fasting glucose level, Cost component, Pharmacoeconomic analysis

Abstract

Objective: The purpose of this study was to compare the cost-effectiveness of T2DM patients in community health centers (Pusat Kesehatan Masyarakat, Puskesmas) of Rancaekek, Linggar, and Nanjungmekar.

Methods: The medicine was a combination of metformin and glimepiride; the outcome parameter was fasting glucose level, cost components were fee of BPJS class III and transportation cost with the patient's perspective. Pharmacoeconomic method was cost-effectiveness analysis. Respondents were given counseling about the importance of medicine consumption.

Results: There were 60 respondents, which met the inclusion criteria, then grouped by gender (male (15%) and female (85%)) and age (the highest incidence was the range from 56 to 65 y old, 36.67%). The average cost-effectiveness ratio of Prolanis in the Puskesmas of Rancaekek, Linggar, and Nanjungmekar was 1,073, 956 and 1,885 IDR per decreased glucose level, respectively. The statistical analysis of decreased blood glucose was 0.341 and the Prolanis cost was 0.399, which no difference between decreased blood glucose and Prolanis costs in the three Puskesmas.

Conclusions: The Prolanis of Linggar Puskesmas was the most cost-effective compared to the Rancaekek and Nanjungmekar Puskesmas.

Downloads

Download data is not yet available.

References

1. International Diabetes Foundation. IDF Diabetes Atlas: Global burden of diabetes. 9th ed. Brussels, Belgium; 2019. Available from: https://www.diabetesatlas.org. [Last accessed on 20 Feb 2020].
2. American Diabetes Association. Diabetes care in the hospital: standards of medical care in diabetes-2019. Diabetes Care 2019;42:S173-81.
3. Schwinghammer TL. Diabetes mellitus. In: Pharmacotherapy Handbook. 7th ed. Wells BG, DiPiro JT, Schwinghammer TL, DiPiro CV. (eds). Mc Graw Hill Medical, Singapore; 2009. p. 210-27.
4. Idris F. The integration of PT Askes (Persero) type 2 diabetes mellitus preventive program into the health social security organizing agency (BPJS Kesehatan). J Indonesia Med Assoc 2014;64:115-21.
5. President of the Republic of Indonesia. UU No 40 of 2004 about National Social Guarantee System. Available from: https://www.bpjs-kesehatan.go.id/bpjs/dmdocuments/06-PROLANIS.pdf [Last accessed on 20 Feb 2020].
6. Klonoff DC, Schwartz DM. An economic analysis of interventions for diabetes. Diabetes Care 2000;23:390-404.
7. Grosse SD. Assessing cost-effectiveness in health care: the history of the $50,000 per QALY threshold. Value Health 2008;8:165-78.
8. Setiadi. Nursing research concepts and writing. Graha Ilmu, Yogyakarta, Indonesia; 2007.
9. Health BPJS. Guidelines for management of DM type 2 chronic diseases, Jakarta; 2015.
10. BPJS health fees. Available from: https://www.bpjs-kesehatan.go.id/bpjs/pages/detail/2014/13 [Last accessed on 20 May 2019]
11. Tripathi KD. Essentials of medical pharmacology. 7th ed. Jaypee Brothers Medical Publishers, India; 2013.
12. Sharma R, Stano M, Hass M. Adjusting to changes in health: implications for cost-effectiveness analysis. J Health Eco 2004;23:335-51.
13. Alghadir A, Awad H, Al-Elsa E, Alghwiri A. Diabetes risk 10 Y forecast in the capital of Saudi Arabia: canadian diabetes risk assessment questionnaire (CANRISK) perspective. Biomed Res 2014;25:88-96.
14. Awad N, Langi AY, Pandelaki K. Risk factor overview of type II diabetes mellitus patients in endocrine polyclinic/FK-UNSRAT section of general hospital, Prof. Dr. R. Kandou manado period May 2011-October 2011. J e-Biomedik 2013;1:45-9.
15. Wilmot E, Idris I. Early-onset type 2 diabetes: risk factors, clinical impact and management. Ther Adv Chronic Dis 2014;5:234-44.
16. Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: a review of current trends. Oman Med J 2012;27:269-73.
17. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimate for the year 2000 and projections for 2030. Diabetes Care 2004;127:1047-53.
18. Ripsin CM, Kang H, Urban RJ. Management of blood glucose in type 2 diabetes mellitus. Am Fam Physician 2009;79:29-36.
19. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2008;31:173-5.
20. Collier CA, Bruce CR, Smith AC, Lopaschuk G, Dyck DJ. Metformin counters the insulin-induced suppression of fatty acid oxidation and stimulation of triacyglycerol storage in rodents skeletal muscle. Am J Physiol Endocrin Metab 2006;219:182-9.
21. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008; 299:1561-73.
22. Ministry of Health Republic of Indonesia. Guidelines for the Application of Pharmacoeconomic Studies. Jakarta, Indonesia, Ministry of Health of the Republic of Indonesia; 2013.